ALNYLAM PHARMACEUTICALS, INC.

ALNY 10-Q · Q1 2026
API behind this page

ALNY Q1 2026 request

Playground key active
Request URL /api/financials?ticker=ALNY&year=2026&quarter=1
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q1 2026 Q1 2025 YoY
Revenue 1,167,175 594,189 +96.4%
Show Product Lines breakouts
AMVUTTRA 889,931 309,992 +187.1%
AMVUTTRA · Europe 113,313 80,088 +41.5%
AMVUTTRA · Rest of World 74,064 31,940 +131.9%
AMVUTTRA · US 702,554 197,964 +254.9%
GIVLAARI 74,394 66,968 +11.1%
GIVLAARI · Europe 20,290 18,544 +9.4%
GIVLAARI · Rest of World 5,013 4,630 +8.3%
GIVLAARI · US 49,091 43,794 +12.1%
Net revenues from collaborations 82,075 99,185 -17.3%
ONPATTRO 20,481 49,489 -58.6%
ONPATTRO · Europe 7,565 26,541 -71.5%
ONPATTRO · Rest of World 2,750 7,376 -62.7%
ONPATTRO · US 10,166 15,572 -34.7%
Other license programs · Regeneron Pharmaceuticals 39,703 13,323 +198.0%
OXLUMO 51,321 42,089 +21.9%
OXLUMO · Europe 24,390 20,984 +16.2%
OXLUMO · Rest of World 9,966 6,996 +42.5%
OXLUMO · US 16,965 14,109 +20.2%
Product 1,036,127 468,538 +121.1%
Product And Service Other · Roche 1,235 1,216 +1.6%
Research Services Obligation · Regeneron Pharmaceuticals 6,633 13,810 -52.0%
Roche Development Services Obligation · Roche 34,406 15,840 +117.2%
Royalty 48,973 26,466 +85.0%
Total Rare 125,715 109,057 +15.3%
Total TTR 910,412 359,481 +153.3%
Show Counterparty Name breakouts
Other · Collaborative Arrangement 98 31,090 -99.7%
Regeneron Pharmaceuticals 46,336 51,039 -9.2%
Regeneron Pharmaceuticals · Collaborative Arrangement 46,336 51,039 -9.2%
Roche · Collaborative Arrangement 35,641 17,056 +109.0%
Roche · Roche Collaboration and License Agreement 35,641 17,056 +109.0%
Show Type Of Arrangement breakouts
Collaborative Arrangement 82,075 99,185 -17.3%
Cost of Revenue 207,520 70,183 +195.7%
Cost Of Collaboration Manufacturing And Royalties 3,602 858 +319.8%
Research & Development 364,866 265,122 +37.6%
Show Research And Development Expense [Axis] breakouts
Clinical research and outside services 199,139 127,343 +56.4%
Compensation and related 124,298 99,187 +25.3%
Occupancy and all other costs 41,429 38,592 +7.4%
Show Counterparty Name breakouts
Regeneron Pharmaceuticals · Global Strategic Collaboration 11 18.9 -41.8%
Roche · Roche Collaboration and License Agreement 61.2 29.7 +106.1%
Selling, General & Administrative 322,551 239,949 +34.4%
Show Selling, General and Administrative Expense [Axis] breakouts
Compensation and related 163,077 131,437 +24.1%
Consulting and professional services 105,294 64,687 +62.8%
Occupancy and all other costs 54,180 43,825 +23.6%
Total Costs & Expenses 898,539 576,112 +56.0%
Operating Income 268,636 18,077 +1386.1%
Interest Expense -69,286 -58,309 -18.8%
Interest Income 26,598 28,673 -7.2%
Other Non-Operating Income (Expense) -4,295 9,191 -146.7%
Non-Operating Income (Expense) -46,983 -20,445 -129.8%
Income Before Taxes 221,653 -2,368 +9460.3%
Income Tax Expense (Benefit) -15,662 -15,883 +1.4%
Net Income 205,991 -18,251 +1228.7%
Show Equity Components breakouts
Retained Earnings 205,991 -18,251 +1228.7%
EPS (Basic) 1.55 -0.14 +1207.1%
EPS (Diluted) 1.51 -0.14 +1178.6%
Wtd Avg Shares (Basic) 132,893 129,676 +2.5%
Wtd Avg Shares (Diluted) 138,226 129,676 +6.6%
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax -3,652 1,030 -454.6%
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent -1,234 -4,084 +69.8%
Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent 89 55 +61.8%
Other Comprehensive Income -4,797 -2,999 -60.0%
Show Equity Components breakouts
Accumulated Defined Benefit Plans Adjustment 89 55 +61.8%
Accumulated Net Unrealized Investment Gain Loss -3,652 1,030 -454.6%
Accumulated Other Comprehensive Income -4,797 -2,999 -60.0%
Accumulated Translation Adjustment -1,234 -4,084 +69.8%
Comprehensive Income 201,194 -21,250 +1046.8%

Balance Sheet

Balance Sheet
Metric Q1 2026 Q1 2025 YoY
Current Assets
Cash & Cash Equivalents 1,710,779 1,019,654 +67.8%
Available For Sale Securities Debt Securities Current 1,298,444 1,605,368 -19.1%
Accounts Receivable 883,957 — —
Show Product Lines breakouts
Product 727.2 — —
Show Type Of Arrangement breakouts
Collaborative Arrangement 109,417 — —
Inventory 84,025 65,581 +28.1%
Prepaid Expenses & Other Current Assets 242,103 152,420 +58.8%
Total Current Assets 4,219,308 3,268,258 +29.1%
Non-Current Assets
Property, Plant & Equipment 518,257 498,684 +3.9%
Operating Lease Right-of-Use Assets 189,299 197,233 -4.0%
Deferred Tax Assets 116,960 107,224 +9.1%
Restricted Investments Noncurrent 22,170 68,592 -67.7%
Other Non-Current Assets 63,553 73,820 -13.9%
Total Assets 5,129,547 4,213,811 +21.7%
Current Liabilities
Accounts Payable 126,628 97,399 +30.0%
Accrued Liabilities 946,485 704,165 +34.4%
Operating Lease Liability Current 45,661 46,011 -0.8%
Deferred Revenue (Current) 3,213 — —
Show Product Lines breakouts
Research Services Obligation · Regeneron Pharmaceuticals 3.2 — —
Show Type Of Arrangement breakouts
Collaborative Arrangement 3,213 — —
Royalty And Development Funding Liability Current 227,488 — —
Show Product Lines breakouts
Vutrisiran 98.5 — —
Zilebesrian 7.5 — —
Show Counterparty Name breakouts
Blackstone Group Inc. 121.5 — —
Total Current Liabilities 1,349,475 1,075,623 +25.5%
Non-Current Liabilities
Operating Lease Liabilities 218,025 230,061 -5.2%
Convertible Debt Noncurrent 1,009,372 1,025,566 -1.6%
Royalty And Development Funding Liability Noncurrent 1,469,684 — —
Show Product Lines breakouts
Vutrisiran 89.4 — —
Zilebesrian 12.1 — —
Show Counterparty Name breakouts
Blackstone Group Inc. 1.37 — —
Other Non-Current Liabilities 7,611 5,871 +29.6%
Total Liabilities 4,054,167 4,098,376 -1.1%
Long-Term Debt (Q) — — —
Show Debt Instrument breakouts
2028 Notes · Convertible Debt 648.5 — —
Convertible Senior Notes Due 2027 · Convertible Debt 360.9 — —
Stockholders' Equity
Common Stock 1,334 1,303 +2.4%
Additional Paid In Capital Common Stock 7,595,473 7,496,876 +1.3%
Accumulated Other Comprehensive Income -24,894 -37,517 +33.6%
Retained Earnings -6,496,533 -7,345,227 +11.6%
Total Stockholders' Equity 1,075,380 426,140 +152.4%
Show Equity Components breakouts
Accumulated Defined Benefit Plans Adjustment -3,179 -4,194 +24.2%
Accumulated Net Unrealized Investment Gain Loss -292 2,574 -111.3%
Accumulated Other Comprehensive Income -24,894 -37,517 +33.6%
Accumulated Translation Adjustment 11,369 -3,105 +466.2%
Additional Paid In Capital 7,595,473 7,496,876 +1.3%
Common Stock 1,334 1,303 +2.4%
Loss on Investment in Joint Venture -32,792 -32,792 0.0%
Retained Earnings -6,496,533 -7,034,522 +7.6%
Total Liabilities & Equity 5,129,547 4,213,811 +21.7%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q1 2026 YTD Q1 2025 YoY
Operating Activities
Depreciation Amortization And Accretion Net 13,553 14,405 -5.9%
Non Cash Interest Expense On Sale Of Future Royalties 66,236 54,625 +21.3%
Stock-Based Compensation 70,154 56,712 +23.7%
Deferred Income Taxes 9,310 9,639 -3.4%
Other Operating Activities Cash Flow Statement 2,994 -19,354 +115.5%
Change in Accounts Receivable -110,421 -7,434 -1385.4%
Change in Inventory -3,324 6,215 -153.5%
Change in Prepaid & Other Assets -6,323 -32,769 +80.7%
Increase Decrease In Accounts Payable And Accrued Liabilities -176,033 -157,735 -11.6%
Change in Deferred Revenue -1,633 -27,321 +94.0%
Net Cash from Operations 70,504 -120,312 +158.6%
Investing Activities
Capital Expenditures -21,833 -8,970 -143.4%
Purchases of Investments -261,625 -401,642 +34.9%
Proceeds From Sale And Maturity Of Marketable Securities 213,191 524,381 -59.3%
Proceeds From Sale Of Restricted Investments 48,825 48,825 0.0%
Payments To Acquire Restricted Investments -4,100 -48,825 +91.6%
Net Cash from Investing -25,542 113,769 -122.5%
Financing Activities
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options 13,157 49,365 -73.3%
Proceeds From Sale Of Royalties Interest 6,000 — —
Repayment Of Liabilities Related To The Sale Of Future Royalties And Development Funding -3,434 -3,283 -4.6%
Proceeds From Payments For Other Financing Activities -9 — —
Net Cash from Financing 15,714 46,082 -65.9%
Supplemental
Interest Paid 64,200 68,931 -6.9%
Income Taxes Paid 2,369 2,969 -20.2%
Unpaid Capital Expenditures 9,185 3,650 +151.6%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents -7,064 14,058 -150.2%
Net Change in Cash 53,612 53,597 0.0%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 1,712,419 1,022,249 +67.5%

Values in thousands USD. Source: SEC EDGAR 10-Q filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key